EvoLVcell featured in PharmaSource Industry Analysis
EvoLVcell, VIVEbiotech’s stable producer cell line (SCL) generation platform, is highlighted in PharmaSource’s analysis of technological innovation across the CDMO sector.
VIVEbiotech is pleased to be featured in PharmaSource’s latest analysis of key trends across the global Contract Development and Manufacturing Organization (CDMO) sector.
The report highlights the growing importance of proprietary technologies and specialized platforms as differentiating factors within the CDMO landscape, particularly in advanced therapy manufacturing. Within its review of technology developments during H1 2026, PharmaSource features EvoLVcell, VIVEbiotech’s stable producer cell line (SCL) generation platform, among a select group of viral vector and gene therapy technologies highlighted in the analysis.
This recognition reflects the increasing relevance of innovative manufacturing platforms in supporting the development and commercialization of advanced therapies. We are delighted to see EvoLVcell recognized alongside other technologies contributing to the evolution of the cell and gene therapy sector.
At VIVEbiotech, we remain committed to advancing lentiviral vector manufacturing through innovation, scientific expertise, and scalable solutions that help developers move their gene therapy programmes from development through clinical and commercial milestones.
As the cell and gene therapy field continues to evolve, robust manufacturing platforms will continue to play a critical role in accelerating the delivery of transformative therapies to patients worldwide.
Read the full PharmaSource article: https://pharmasource.global/content/news/cdmo-news/the-us-reshoring-tide-goes-out-record-cdmo-newsflow-but-the-investment-moved-back-offshore-in-h1-2026/
